$5.15 0.00 (0.00%) TG Therapeutics Inc - NASDAQ

Dec. 7, 2016 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 5.15
Trade Time: Dec 07 04:00 PM Eastern Daylight Time
Change: +0.00 (0.00%)
Prev Close: 5.15
Open: 5.60
Bid: 4.15
Ask: 5.40
  1. No results found.
  1. Morning Call For October 13, 2016

    TalkMarkets | Oct. 13, 2016 | 08:10AM EST
  2. Jim Cramer Dishes On Microsoft, Gilead, TG Therapeutics & NY Community Bancorp

    Benzinga | Jan. 24, 2016 | 19:56PM EST
  3. TG Therapeutics, Inc. Announces Oral Presentation of Novel Pre-Clinical Combinations With TGR-1202 by Investigators at Columbia University

    Benzinga | Dec. 7, 2015 | 11:30AM EST
  4. TG Therapeutics Announces Data Presentations from Ongoing Clinical Studies in Patients With NHL, CLL at #ASH2015

    Benzinga | Dec. 6, 2015 | 18:57PM EST
  5. Mid-Morning Market Update: Markets Mostly Flat; Rite Aid Earnings Miss Views

    Benzinga | Sep. 17, 2015 | 09:35AM EST
  6. TG Therapeutics, Inc. Launches Phase 1/2 "Triple-Therapy" Study With TGR-1202 + TG-1101 + the PD-1 Checkpoint Inhibitor Pembrolizumab in Patients With Advanced Chronic Lymphocytic Leukemia (CLL) at the University of Pennsylvania's Abramson Cancer Center

    Benzinga | Sep. 9, 2015 | 07:32AM EST
  7. TG Therapeutics to Present Clinical Data on TG-1101 and TGR-1202 at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma

    Benzinga | Jun. 11, 2015 | 15:31PM EST
  8. Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG ...

    GuruFocus | Jun. 1, 2015 | 16:15PM EST
  9. TG Therapeutics Announces the Triple Combination of TG-1101, TGR-1202 and Ibrutinib is Safe and Highly Active in Patients With Advanced B-Cell Malignancies

    Benzinga | Jun. 1, 2015 | 10:00AM EST
  10. TG Therapeutics, Inc. Presents Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research Annual Meeting

    Benzinga | Apr. 20, 2015 | 06:31AM EST
  11. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

    Benzinga | Jan. 13, 2015 | 11:34AM EST
  12. The Top 5 Biotech Gainers Of 2014

    Benzinga | Dec. 29, 2014 | 14:15PM EST
  13. Wainwright Sees TG Therapeutics As Take-Out Target

    Benzinga | Oct. 27, 2014 | 12:20PM EST
  14. UPDATE: H.C. Wainwright Initiates Coverage On TG Therapeutics On Significant Long-Term Upside

    Benzinga | Oct. 27, 2014 | 07:19AM EST
  15. TG Therapeutics Announces Exercise of License Option For Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202

    Benzinga | Sep. 23, 2014 | 06:31AM EST
Trading Center